28 results about "Corticosterone" patented technology

The application belongs to the technical field of medicines, and specifically discloses an anti-depression m-hydroxybenzoic acid compound and a preparation method and application thereof; the m-hydroxybenzoic acid compound Hyperioxides A-F provided by the application has not been reported; the six compounds have good anti-depression effects, and further research shows that the compounds Hyperioxide A, Hyperioxide D, Hyperioxide E and Hyperioxide F have significant protective effects on SH-SY5Y cells induced by corticosterone, and are superior to positive drugs fluoxetine and Luoyoutei, and can be used for developing drugs for treating depression.

The invention discloses application of Cacumen biotae-derived extracellular vesicles in preparation of drugs for treating anxiety, depression or insomnia. The EVs are separated and purified from cacumen biotae through a specific differential ultracentrifugation method, the EVs have a typical double-layer membrane structure, the average particle size is about 100 nm, about 1012 EVs can be extracted from each gram of cacumen biotae, and 62 volatile components are contained. Cacumen biotae EVs can be taken by PC12 cells, and corticosterone-induced neuron damage can be relieved; for chronic constraint stress model mice, anxiety behaviors and spatial learning and memory disorders can be improved, and central nervous inflammation can be inhibited; for chronic unpredictable mild stress model mice, the weight, the sucrose preference rate and the cognitive ability can be recovered, and the levels of 5-hydroxytryptamine and gamma-aminobutyric acid are increased; and for 4-chloro-DL-phenylalanine induced insomnia model mice, the sleep condition can be improved, the neurotransmitter level can be recovered, and the effect is equivalent to that of positive drugs such as citalopram, fluoxetine, diazepam and the like.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The invention provides an essential oil composition for relieving depressive symptoms and a preparation method and application thereof, and belongs to the technical field of essential oil compositions. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 1-9 parts of perilla frutescens, 1-9 parts of rhizoma cyperi, 1-9 parts of pericarpium citri reticulatae and 1-9 parts of liquorice. The essential oil composition provided by the invention has a kidney channel protection effect, can reduce the rising corticosterone level in the body, alleviates the neuroendocrine dyscrasia related to depression by adjusting the hypothalamus-pituitary-adrenal axis (HPA axis) function, and can improve the appetite and metabolic state of the body at the same time.

The invention discloses application of a ganoderma lucidum extract in preparation of a product for improving skin problems, bidirectional regulation of skin homeostasis is realized through a dual-action mechanism, on one hand, conversion of corticosterone to cortisol is inhibited, and on the other hand, the skin homeostasis is inhibited; the problems of skin barrier injury, skin basement membrane injury, excessive sebum secretion, accelerated aging and the like caused by excessive cortisol are relieved; on the other hand, by inhibiting differentiation of macrophages induced by noradrenaline to inflammation phenotypes, the cortisol level is reduced, meanwhile, the skin inflammation response excited by early pressure is effectively controlled, and bidirectional regulation of skin homeostasis is achieved.

This invention discloses the application of prostaglandin A2 in the preparation of drugs for treating anxiety disorders and the related pharmaceutical formulation. It belongs to the field of biomedical technology, and specifically relates to the application of prostaglandin A2 in the preparation of drugs for treating anxiety disorders. Through chronic restraint stress (CRS) mouse models, corticosterone-induced (CORT)-damaged PC12 cell models, and multi-level molecular, circuit, and behavioral analyses, this invention demonstrates that prostaglandin A2 can exert multi-target anti-anxiety effects at the levels of overall behavior, cellular function, neural circuit structure, and molecularity. Prostaglandin A2 can treat anxiety disorders by improving anxiety-like behaviors and reversing behavioral phenotypic damage.

CED-based methods, products and compositions for treating glioblastoma with anti-inflammatory therapeutics and chemotherapeutics without decreasing brain corticosterone compared to systemic delivery of dexamethasone, and not causing splenal atrophy and / or adrenal atrophy.

The invention relates to the field of biological medicine, and discloses application of cycloastragenol in preparation of a medicine for treating lung adenocarcinoma combined anxiety depression. According to the application, cycloastragenol is found to relieve anxiety and depression symptoms by adjusting the level of corticosterone and other stress hormones; the anti-tumor immune response is enhanced by inhibiting the depletion of CD8 + T cells; and the anti-tumor capability of the CD8 + T cells is recovered by inhibiting the expression of Fabp5, so that a new idea and a potential drug choice are provided for clinical treatment of lung adenocarcinoma combined anxiety depression.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The invention discloses an application of parabacteroides gore outer membrane vesicles in preparation of drugs for neuroprotection and / or anxiety disorder improvement. Researches show that the parabacteroides gore outer membrane vesicles can effectively antagonize corticosterone-induced nerve cell injury, can relieve anxiety-like behaviors of chronic constraint stress mice, and have good neuroprotection and anxiety-resistant activity. The invention provides a new drug choice for clinically treating nerve injury and relieving anxiety disorder, and has a wide application prospect in the aspect of treating nervous system diseases.

This invention discloses the application of a natural isoflavone compound in the preparation of drugs for the prevention or treatment of depression. The natural isoflavone compound is hematoxylin A, a derivative of hematoxylin A, or a pharmaceutically acceptable salt of hematoxylin A. Hematoxylin A can effectively reduce oxidative damage to HT22 neurons in the hippocampus induced by glutamate and corticosterone, and can significantly improve the behavioral performance of mice in a chronic restraint stress depression model, exhibiting clear antidepressant activity. Hematoxylin A has a well-defined structure and good safety profile, showing promising application prospects in the development of antidepressant drugs.

The invention discloses walnut meal protein peptide with dual activities of reducing blood sugar and resisting depression and application of the walnut meal protein peptide, and belongs to the technical field of biology. The two kinds of walnut meal protein peptides YALL and HPF are prepared, the two kinds of polypeptides both show the blood glucose reducing potential and the anti-depression activity, the glucose consumption of an HT22 high glucose depression cell model can be increased by inhibiting the activity of alpha-glucosidase, and the blood glucose reducing effect is achieved; by inhibiting the activity of MAO-A, the corticosterone content of an HT22 high-glucose depression cell model can be reduced, the levels of proinflammatory factors IL-6 and TNF-alpha can be effectively reduced, and the anti-depression effect is achieved. The walnut meal protein peptide is derived from walnut processing byproducts, is safe and free of toxic and side effects of chemical drugs, can be used for functional foods or adjuvant therapy drugs, and meets the clinical requirements of diabetes mellitus complicated with depression groups.

The application belongs to the technical field of proteins, and relates to a peptide for promoting synthesis of brain-derived neurotrophic factor (BDNF) and a preparation method and application thereof. The amino acid sequence of the peptide for promoting synthesis of brain-derived neurotrophic factor BDNF is SGFSKHF. The main effect of the peptide is that the peptide can protect CORT (corticosterone) from damaging PC12 cells, can spontaneously bind to a TrkB receptor, the structure of a complex formed after the binding is more stable, helps to activate a BDNF-TrkB-CREB pathway signal transduction, and then promotes generation of BDNF, thereby helping to delay occurrence and development of neurodegenerative diseases.

The invention discloses application of rubber tree seed oil in preparation of a product for improving or treating kidney-yang deficiency, and belongs to the technical field of medicines. The hevea brasiliensis seed oil can improve the levels of serum adrenocorticotropin releasing hormone, adrenocorticotropin and corticosterone by adjusting the hypothalamus-pituitary-adrenal axis function so as to improve the related signs of kidney-yang deficiency, such as intolerance of cold and liking warm, cold limbs, lassitude, reduced autonomous activity and the like. The invention further discloses a composition containing the hevea brasiliensis seed oil. The composition can be prepared into medicines, health-care foods or functional foods. The invention provides a new choice which is single in component, clear in mechanism, safe and effective for the treatment of kidney-yang deficiency.

The present disclosure relates to a strain of Bifidobacterium animalis subsp. lactis HEM20-01 (KCTC14143BP) and a composition for treating, preventing or alleviating depression, comprising the same.A strain of Bifidobacterium animalis subsp. lactis HEM20-01 (KCTC14143BP) according to an embodiment of the present disclosure can treat or prevent depression by reducing corticosterone, endotoxin and pro-inflammatory cytokines. Therefore, the strain can be applied to pharmaceutical compositions, food compositions, health functional food compositions, and the like for treating or preventing depression.

The application discloses a 21-hydroxylase deficiency screening kit and application thereof, relates to the blood analysis technical field, and a steroid hormone marker composition of 21-hydroxylase deficiency, wherein the nine markers comprise 17alpha-hydroxyprogesterone, androstenedione, 11-deoxycortisol, 21-deoxycortisol, cortisol, corticosterone, progesterone, dihydrotestosterone and 11-deoxycorticosterone; the kit can be used for screening 21-hydroxylase deficiency, 11beta-hydroxylase deficiency, 17alpha-hydroxylase deficiency and other types of diseases; the kit comprises detection components for detecting the hormones; compared with a traditional time-resolved fluorescence immunoassay method, the LC-MS / MS multi-index combined detection scheme adopted in the application can significantly reduce false positive results; and invalid recall, unnecessary family anxiety and medical burden caused by false positive results are greatly reduced.

This invention belongs to the field of traditional Chinese medicine and natural product technology, specifically relating to the use of Leonurus japonicus extract in the preparation of antidepressant drugs. This invention uses 70% ethanol extraction to prepare Leonurus japonicus extract. This extraction method reduces extraction costs, shortens production time, increases extract yield, increases the extraction rate of effective components, and increases enterprise production efficiency. This invention also uses multiple depression models to verify the antidepressant activity of Leonurus japonicus extract, including a chronic unpredictable mild stress-induced depression model, a chronic corticosterone injection-induced depression model, and an ovariectomy combined with hormone withdrawal-induced depression model. The results show that Leonurus japonicus extract has a significant antidepressant effect in experimental animals. The antidepressant effect of the Leonurus japonicus extract of this invention is not obvious compared to the characteristics of traditional gynecological drugs, and it focuses on hormone-related depression, demonstrating the therapeutic value of Leonurus japonicus extract in the clinical classification of depression.

The invention relates to the technical field of medicines, in particular to an application of Neoline in quickly taking effect and resisting depression. The C19 type diterpenoid alkaloid Neoline provided by the invention shows remarkable and quick-acting anti-depression activity in both a corticosterone-induced mouse depression model and a chronic constraint stress mouse depression model, the drug effect is equivalent to that of a positive drug esketamine ((S)-Ketamine), but the effective dose is far lower than that of the positive drug (S)-Ketamine, and the C19 type diterpenoid alkaloid Neoline can be orally taken, so that the C19 type diterpenoid alkaloid Neoline can be used for treating depression. The medicine compliance and usability are better, and the compound can be used for developing anti-depression medicines which take effect quickly.

The invention discloses an application of luteolin in preparation of a medicine for improving cognitive impairment induced by corticosterone (Cort), and relates to a medicine for improving cognitive impairment induced by corticosterone (Cort). By constructing a mouse cognitive impairment model induced by chronic Cort, research proves that the luteolin can remarkably improve the spatial learning and memory ability of a model mouse. The action mechanism is related to a multi-target synergistic effect, and mainly comprises the steps of relieving oxidative stress injury, inhibiting hippocampal neuron apoptosis, adjusting the autophagy level and enhancing synaptic plasticity. The new application and multi-mechanism synergistic effect of the luteolin for improving the Cort-induced cognitive impairment are defined, and a new technical scheme is provided for developing safe and effective cognitive impairment treatment medicines.

The invention provides a pharmaceutical composition and application thereof in preparation of antidepressant drugs, and relates to the technical field of biological medicines. The pharmaceutical composition is composed of isodendrobiin, naringenin and glycyrrhizic acid, the three components have a synergistic effect, and the pharmaceutical composition has a significant advantage on the protection effect on a corticosterone-induced HT22 cell injury model, can effectively improve the cell viability decline of neuronal cells induced by corticosterone, and alleviates the cell apoptosis of HT22 cells caused by corticosterone. The pharmaceutical composition also has a significant improvement effect on depression-like behaviors of a depression mouse model, and can significantly reduce neuronal nucleus fixation and shrinkage and cell body shrinkage of the depression mouse model and restore the conditions of neuron volume reduction and nissl body number reduction. Meanwhile, the levels of neurotransmitters 5-HT, NE and DA in brain tissues of a depression mouse model are increased. The pharmaceutical composition provided by the invention provides a new strategy for treating or improving depression.

The present invention belongs to the technical field of plant extraction. Disclosed are a medium-chain inulin, a preparation method therefor, and the use thereof. The unique inulin structure and chain length disclosed in the present invention reshape the gut microbiome and metabolome, and in particular, selectively modulate key microorganisms such as Faecalibacterium, Bifidobacterium, Parabacteroides, Clostridium_sensu_stricto_1 and Akkermansia, and metabolites such as nicotinamide, taurocholic acid, aldosterone, corticosterone, 2-(1H-indol-3-yl)acetic acid, 5-hydroxy-L-tryptophan, 5α-DHT and maltose, thereby promoting the amelioration of obesity and the improvement of the overall health of a host. The core microorganisms and metabolites identified by the technical solution represent potential therapeutic targets for preventing or treating obesity and related metabolic symptoms. These findings support the development of inulin-based nutritional strategies to effectively manage body weight by modulating specific microbiota and the metabolome.

The invention discloses a serum-free additive E6 for a chicken primordial germ cell culture medium and application of the serum-free additive E6, and belongs to the technical field of animal husbandry and biology. The E6 serum-free additive is composed of six components necessary for in-vitro proliferation of chicken PGCs, and specifically comprises DL-alpha-tocopheryl acetate, BSA (fatty acid-free component V), human recombinant insulin, corticosterone, linolenic acid and triiodothyronine. After the E6 serum-free additive is added into a chicken PGCs culture medium, the basic form of cells can be effectively maintained, long-term in-vitro proliferation of the cells is supported, expression of specific marker genes and proteins such as reproduction and pluripotency is maintained, and meanwhile the long-term subculture capacity and gonad migration potential of the PGCs are guaranteed. The E6 serum-free additive disclosed by the invention has the advantages of simple and clear components, simplicity and convenience in preparation and relatively low cost, and can be widely applied to the fields of poultry germplasm resource preservation, gene editing, biological breeding and the like.

This invention discloses the use of lemon essential oil in the preparation of drugs that enhance corticosterone-induced cell viability and have antidepressant effects, belonging to the field of plant essential oil technology. This invention discovers that lemon essential oil can effectively inhibit corticosterone-induced apoptosis in PC12 cells and promote their proliferation.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 neuron cells and hCMEC / D3 brain microvascular endothelial cells injured by oxygen-glucose deprivation (OGD) induction, and can resist the injury of PC12 cells induced by corticosterone (CORT) and MPP + , and effectively inhibit the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, and can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve and vascular units.

Provided are a Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease and a use thereof, and the Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease is named as Bifidobacterium longum subsp. infantis BI03 strain, with a deposit number of CGMCC No. 24473 and deposit date of Mar. 7, 2022. The strain can significantly alleviate the symptoms of Parkinson's disease, specifically manifested in: alleviating Parkinson's disease-related dyskinesia and corticosterone elevation; weakening the neuroinflammation associated with Parkinson's disease; promoting glutathione and weakening brain oxidative stress damage.

The invention provides a biomarker for diagnosing depression and application thereof. Experiments prove the relationship between HPA / corticosterone / glucocorticoid receptor / GNMT / glycine and sarcosine, the HPA / corticosterone and sarcosine are in negative correlation regulation, and the glucocorticoid receptor / GNMT / glycine and sarcosine are in positive correlation regulation. The invention also provides a biomarker capable of effectively diagnosing depression. The biomarker comprises sarcosine, methyl stearate and LysoPE (16: 1 (9Z) / 0: 0) in the exosome. Besides, the depression animal model is constructed by reducing GNMT, and the depression animal model can be used for depression drug screening, efficacy evaluation or diagnosis, and can also be used for researching and revealing the pathogenesis of depression. The invention has important significance on the diagnosis and treatment of depression, and has wide application prospects in clinic.

The application belongs to the technical field of medicines, and specifically discloses a novel chalcone compound, a preparation method, a pharmaceutical composition and application thereof; the chalcone compounds (+)‑lupulusone D and (‑)‑lupulusone D provided by the application have not been reported so far. Experimental results show that the chalcone compounds (+)‑lupulusone D and (‑)‑lupulusone D provided by the application have a significant protective effect on SH‑SY5Y cells induced by corticosterone, and are obviously superior to a positive drug fluoxetine, and can be used for developing a drug for treating depression.